



March 10, 2025

Via CM/ECF and Hand Delivery

The Honorable Jennifer L. Hall
J. Caleb Boggs Federal Building
Unit 17, Room 6312
844 North King Street
Wilmington, DE 19801-3555

**Re: *Ingenus Pharmaceuticals, LLC, and Leiutis Pharmaceuticals LLP
v. Accord Healthcare, Inc., C.A. No. 23-377-JLH***

Dear Judge Hall:

We represent Plaintiffs Ingenus Pharmaceuticals, LLC and Leiutis Pharmaceuticals LLP (“Ingenus”) in the above-referenced matter. We write jointly with Defendant Accord Healthcare, Inc. in reference to Your Honor’s February 25, 2025 Order After Pretrial Conference. On the following issues, the parties have met and conferred and state as follows:

Trial Time

Ingenus respectfully requests 7.5 hours of trial time per side. As stated at the PTC, Accord believes it will use no more than 5 hours, but does not object to Ingenus’ request.

Deposition designations

The parties estimate that in addition to the above trial time, the parties presently plan to introduce approximately 60 minutes of testimony through deposition designations.

Closing arguments

The above requested trial time does not include closing arguments. The parties do not request closing arguments but are available to do so at the Court’s convenience.

Confidential information

The parties do not expect to request to seal the courtroom during trial. To protect any confidential information, the parties will work together to avoid displaying specific confidential information on the courtroom displays and screens..

Respectfully submitted,

/s/ Daniel A. Taylor
Daniel A. Taylor (No. 6934)

cc: All Counsel of Record (via CM/ECF and email)